Cedars-sinai Medical Center

Synthetic Biologics, Inc.

Other

Mark Pimentel

Henry C Lin

Christopher Chang

Ruchi Mathur

Ali Rezaie

Vince Wacher

Gil Y Melmed

Steve Kanzer

Kapil Gupta

Gabriela Guimaraes Sousa Leite

Mark Sasha Drlik

Nathan John Muller

Nicholas David Allan

Kenneth Maccallum

Nigel Anthony Syrotuck

Jeffrey Conklin

Edy E Soffer

Martin Juergen Kellinghusen

Daniel Furst

Kristofor Dyck Dolberg

Nipaporn Pichetshote

Laith Jamil

Simon Lo

Srinivas Gaddam

Methods and systems one or more for performing intra-luminal ultraviolet therapy for treating and/or ameliorating a gastrointestinal tract inflammation and/or infection are provided. In one example, a light delivery catheter may include a light emitting portion and non-illuminating portion, wherein the light emitting portion may include one or more UV transparent balloons. In some examples, the UV light source is configured to emit narrow-band light having wavelengths in a range between 335 nm and 349 nm.

Internal ultraviolet therapy

Described herein are methods of detecting levels hydrogen sulfide (HS) to diagnose HS positive disease or conditions. Examples of HS positive diseases and conditions include small intestinal bacterial overgrowth, diarrhea, fatigue, bowel urgency and abdominal pain. The HS level can guide treatments for subjects who have high levels of HS.

Measurement of hydrogen sulfide during breath testing

The disclosed technology relates to a system for delivering UV-A/B light with a catheter to treat infectious or inflammatory disorders in a patient. While UV light in the UV-C range has traditionally been used to treat skin disorders and for focused ablation of plaques in the arteries and other targeted internal uses, it has not been developed for broader infection, inflammation or neoplasia treatment inside the human body. Here, the inventor(s) developed a system for emission of therapeutic doses of UV light via a catheter, capsule, endoscope, tube or port that can be used to manage internal infections and inflammatory conditions inside a patient.

Systems and methods have been developed for implementation of a breath testing system for convenient sampling of intestinal gases exhaled from a patient's breath. This may include a system with a manifold that includes thermal regulation components, for instance thermistors and resistive heating elements, which maintain the temperature of the gases above the body temperature of the patient. In some examples, the system will determine an indication of whether a patient has SIBO by adjusting a change in exhaled hydrogen concentration by a methane level exhaled by a patient.

Breath gas analysis

Described herein are methods of diagnosing systemic sclerosis (SSc) involving the detection of anti-vinculin antibodies. Also described herein are methods of selecting treatment of subjects diagnosed with systemic sclerosis (SSc), and methods of treating systemic sclerosis (SSc).

Diagnosis of scleroderma

The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens

A UV light delivery device for performing intra-corporeal ultraviolet therapy is provided. The device includes an elongated body separated by a proximal end and a distal end. The device also includes a UV light source configured to be received at the receiving space. In some examples, the UV light source is configured to emit light with wavelengths with significant intensity between 320 nm and 410 nm and is utilized in conjunction with an endotracheal tube or a nasopharyngeal airway.

Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.

Methods for detecting post-infectious irritable bowel syndrome

The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.

Anti-methanogenic lovastatin analogs or derivatives and uses thereof

The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.

Anti-methanogenic compositions and uses thereof

Systems and methods have been developed for implementation of a portable SIBO testing system for convenient sampling of intestinal gases exhaled from a patient's breath. These devices may be in the form of a hand held meter that would integrate with a smartphone or other device with an application that can record data relating to food consumed by a user. Various technologies may be utilized to measure the levels of gases exhaled by a user, which may include (1) sorbent based technology and (2) membrane based technology. In some examples, the system will determine an indication of whether a patient has SIBO by adjusting a change in exhaled hydrogen concentration by a methane level exhaled by a patient.

Disclosed are methods of diagnosing constipation and constipation-predominant irritable bowel syndrome by screening for the presence of abnormally high levels of methane and/or methanogenic organisms in a subject.

Growing community of inventors

Los Angeles, CA, United States of America

Mark Pimentel